Rodman & Renshaw Outperform On Curis, Inc.

Rodman & Renshaw has an Outperform rating and a $6 price target on shares of Curis, Inc. CRIS. In a note to clients, Rodman & Renshaw writes, "We are reiterating our Market Outperform / Speculative Risk rating and a 12-month target price of $6. Our price target is derived from a comparables analysis with other similarly staged biotechnology companies, in addition to an NPV analysis of the BCC revenue potential. Today's top-line pivotal study results, taken together with a prior Phase 1 trial evaluating vismodegib that yielded a 55% response rate in 33 advanced BCC patients, as well as highly statistically significant results from a randomized Phase 2 trial evaluating vismodegib in Gorlin syndrome, collectively establish a profile of a highly efficacious inhibitor for a range of BCC patients." At last check, shares of CRIS were up 2 cents to $3.34.